Back to today’s briefing

Story perspectives

FDA Approves JN.1 Focus, Delays COVID Vaccine Rollout

5/24/2025

41 5

Left

FDA Approves JN.1 Focus

The FDA's advisory committee has given a green light to focus on the JN.1 virus family for future COVID-19 vaccines. Yet, new regulations may slow down the rollout for healthy individuals under 65, sparking worries about timely access. Experts stress the urgency for effective vaccines to combat rapidly changing strains and protect younger populations.

Center

FDA Restricts Vaccine Access

The FDA is tightening COVID-19 vaccine access for healthy individuals under 65, prioritizing seniors and high-risk groups. New randomized trials will be necessary for wider approval, sparking worries about vaccine availability. While this move seeks to harmonize U.S. policy with global standards, it could delay protection for those eager to safeguard their health.

1 of 2

FDA Approves JN.1 Focus

The FDA's advisory committee has given a green light to focus on the JN.1 virus family for future COVID-19 vaccines. Yet, new regulations may slow down the rollout for healthy individuals under 65, sparking worries about timely access. Experts stress the urgency for effective vaccines to combat rapidly changing strains and protect younger populations.

1 / 2